Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
GlobalData on MSN4d
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP useLenacapavir is already approved under the name Sunlenca as an HIV treatment for patients resistant to other medication ...
News Medical on MSN3d
New HIV therapy lenacapavir shows high efficacy in Ugandan populationA multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
CompanyOverview\|NASDAQ:GILD] Gilead Sciences Inc. (NASDAQ: GILD) stock surged to a new 52-week high at $106.69 recently on ...
A multi-national, multi-institutional study investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.
Health sector stocks fluctuate amid DOJ probe into UnitedHealth (UNH), Gilead upgrade for HIV treatments, and Moderna's focus on non-COVID approvals.
Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving ...
Twice-yearly lenacapavir PrEP could be available as early as this summer pending federal Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback